



Persistent Asthma: Daily Medication

Assess Control: First check adherence, inhaler technique, environmental factors, and comorbid conditions. Step up if needed; reassess in 4–6 weeks. Step down if possible (if asthma is well controlled for at least 3 consecutive months)



STEPWISE APPROACH TO MANAGING ASTHMA

GetAsthmaHelp.org/GIST

Intermittent Asthma



STEP 1 (ALL AGES)

Preferred:

PRN Shortacting beta-agonist (e.g. albuterol)

AGE 0-4

- Add short course daily ICS at the start of respiratory infection
- Consider inadequate control and the need to step up treatment if SABA used more than 2 days per week (other than for exercise)

STEP 2

(ALL AGES) **Preferred**:

Low-dose ICS & PRN SABA

Alternative:

<u>AGE 12+</u>

Add concomitant ICS PRN

AGE 12+

PRN SABA +

- LTRA*
- Cromolyn*
- Nedocromil*
- Zileuton*
- Theophylline*

AGE 5-11

PRN SABA +

- LTRA*
- Cromolyn*
- Nedocromil*
- Theophylline*

AGE 0-4

Montelukast* or Cromolyn & PRN SABA

STEP 3

Preferred:

AGE 12+ & 5-11

Combination low-dose ICS-formoterol daily & PRN

AGE 0-4

- Low-dose ICS-LABA & PRN SABA
- Medium-dose ICS, & PRN SABA
- Montelukast*+ low-dose ICS

Alternative:

AGE 12+

PRN SABA +

- · Medium dose ICS
- Low-dose ICS-LABA
- Low-dose ICS + LAMA or LTRA* or Theophylline* or Zileuton*

AGE 5-11

- Medium dose ICS & PRN SABA
- Low-dose ICS-LABA
- Low-dose ICS + LTRA*
- Low-dose ICS
 Theophylline
- +Theophylline,*
 & PRN SABA

STEP 4

Preferred:

AGE 12+

Combination medium-dose ICS-formoterol daily & PRN

AGE 5-11

Combination medium-dose ICS-formoterol daily & PRN

AGE 0-4

Medium-dose ICS-LABA & PRN SABA

Alternative:

<u>AGE 12+</u>

PRN SABA +

- Medium dose ICS-LABA
- Medium dose ICS + LAMA or LTRA* or Theophylline*

<u>AGE 5-11</u>

- Medium dose ICS-LABA & PRN SABA
- Medium dose ICS + LTRA*
- Theophylline* + Medium dose ICS & PRN SABA

AGE 0-4

Montelukast *+ medium dose ICS * & PRN SABA

STEP 5

Preferred:

AGE 12+ Medium-high dose ICS-LABA+ LAMA &

AGE 5-11 High-dose ICS-LABA & PRN SABA

AGE 0-4

PRN SABA

High-dose ICS-LABA & PRN SABA

Alternative:

AGE 12+ PRN SABA +

- Medium-high dose ICS-LABA
- High dose ICS + LTRA*

AGE 5-11

- High-dose ICS + LTRA*
- Theophylline* + High-dose ICS & PRN SABA

AGE 0-4

High-dose ICS + montelukast* & PRN SABA

STEP 6

Preferred:

AGE 12+

High-dose ICS-LABA + oral corticosteroid & PRN SABA

AGE 5-11

High-dose ICS-LABA

+ oral corticosteroid & PRN SABA

AGE 0-4

High-dose ICS-LABA + oral systemic corticosteroid & PRN SABA

Alternative:

AGE 5-11

- High-dose ICS +
 LTRA* + oral
 corticosteroid
- Theophylline* + high-dose ICS + oral corticosteroid & PRN SABA

AGE 0-4

Montelukast*+ highdose ICS + oral systemic corticosteroid & PRN SABA

Children 4 years and older may use Step 3 & Step 4 for children ages 5-11

Steps 2, 3 and 4. Ages 5+: Subcutaneous immunotherapy may be used as an adjunct treatment to standard medications in patients whose asthma is controlled at the initiation, build up and maintenance phases of immunotherapy

Steps 5 and 6: Consider appropriate asthma biologic treatment

* Cromolyn, Nedocromil, LTRAs including Zileuton and montelukast, and Theophylline were not considered for the 2020 update, and/or have limited availability for use in the U.S., and/or have an increased risk of adverse consequences and need for monitoring that make their use less desirable.

Reference: National Heart, Lung, and Blood Institute's Expert
Panel Report 3: Guidelines for the Diagnosis and Management of Asthma 2007,
and Asthma Management Guidelines: Focused Updates 2020.
This tool was adapted from the Colorado Clinical Guidelines Collaborative.